Roger S. Blumenthal, MD, is director, Ciccarone Center for the Prevention of Heart Disease

It was not until Virchow identified the cellular contributions to thrombosis that physicians began to visualize arteries as dynamic tissues.

Numerous clinical trials have shown that HMG CoA reductase inhibitor (statin) therapy reduces the risk of myocardial infarction (MI), stroke, and mortality in patients with cardiovascular disease.

Elderly patients with a history of an acute coronary syndrome (ACS) are at higher risk for subsequent cardiovascular events than younger patients.